ClinicalTrials.gg
WithdrawnNCT03275012GABA-2Updated Dec 2, 2019

Efficacy and Safety Study of Gabapentin as add-on to Morphine in Paediatric Patients Affected by Chronic Pain

A Phase 2 interventional study of Gabapentin + Morphine and Placebo + Morphine in Chronic Pain, sponsored by Pharmaceutical Research Management srl. Withdrawn. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2019-12-02.

Sponsored by Pharmaceutical Research Management srl · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study not started

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2017, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
3 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing gabapentin in Chronic Pain — none open to participants now, none under way, none of them phase 3. Gabapentin · Chronic Pain.

Enrollment
10th of 10
0 · median 43
Started
2017
the only one that year
Phase 2
4 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
Pharmaceutical Research Management srl

Among the 10 studies testing gabapentin in Chronic Pain, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 2, and was the 7th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

None of the 10 studies testing gabapentin in Chronic Pain is open now. The open studies under Chronic Pain, anywhere →

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 3 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing gabapentin in Chronic Pain as a file.
02

Study summary

The objective of the study is to evaluate the efficacy of gabapentin as adjunctive therapy to morphine in the treatment of severe chronic neuropathic or mixed pain in children from 3 months to less than 18 years of age assessed by the difference in average pain scores between treatment arms at the end of the treatment period.

Read the detailed description

This paediatric trial has the objective to make gabapentin available for children with severe chronic neuropathic or mixed pain. This study will be conducted in full conformance with the ethical principles outlined in the Declaration of Helsinki, consistent with ICH-GCP (including ICH Topic E11 guideline) and applicable regulatory requirements including the Paediatric Recommendations (CE/2008).

Gabapentin has been successfully used to treat neuropathic pain in adults. In absence of specific paediatric studies it is not approved for the same condition in children.

The paediatric use of gabapentin is hampered by: a) the lack of a suitable paediatric formulation, b) the significant variability of gabapentin PK profile and c) efficacy and safety data in this specific population.

GABA-2 is a superiority trial designed to assess the potential benefit of gabapentin oral solution in augmenting the analgesic effect of morphine in children affected by severe chronic pain thus preventing or decreasing opioid tolerance, as it has been reported to happen in adults. Thus GABA-2 study is an randomized, double blind, placebo controlled, multi-centre study to evaluate the efficacy of gabapentin added to morphine in paediatric patients suffering from severe chronic pain (neuropathic or mixed with ascertained neuropathic component). The trial will include 66 patients aged from 3 months to less than 18 years affected by severe chronic neuropathic or mixed pain and in need of morphine.

Children from 3 months to \<3 years of age will participate to GABA-2 on the basis of the nature of the underlying disease suggestive of a neuropathic component.

A block randomisation will be applied to assign children to gabapentin and morphine (intervention group) or gabapentin placebo and morphine (control group) in a 1:1 ratio.

Randomisation will be stratified by age-group as follows:

  • 3 months - \< 3 years;
  • 3 years - \< 8 years;
  • 8 years - \< 18 years.

Recruitment will start with patients ≥ 3 years of age. Patients \< than 3 years of age will be recruited when results from the ongoing non-clinical toxicological study in juvenile rats will confirm the safety of gabapentin in the age subset 3 months-3 years.

The protocol has been designed to ensure double-blind conditions at randomisation and throughout the treatment period. Blinding (children, caregiver, outcome assessor) will be ensured by elaborating an identical (matching) gabapentin placebo.

The study comprises 3 stages over 18 to 22 weeks: 1st stage ( screening period of 1 week, wash out phase of max 3 days and baseline assessment of 3 days ), 2nd stage ( treatment period including an optimization phase of 3 weeks and 12 weeks of maintenance), 3rd stage (study taper lasting from 0 to 4 weeks and 1 week follow up).

The proposed formulation of the IMP test is a liquid oral formulation (syrup) containing 75 mg/ml of gabapentin. The IMP comparator is the placebo. The background therapy is morphine presented as immediate and extended-release tablets and a liquid, oral formulation. Every participant will be administered morphine and the active product or placebo.

For both study drugs, dosing will initiate at a starting dose in mg/kg/day and will be increased according to a predefined matrix to a maximum dose in mg/kg/day. Dosing will be flexibly optimised in order to maximise the potential benefits while minimising risk of AEs. There will be a maximum of 5 possible dose adjustments during the 3 weeks optimisation period.

Dosing for gabapentin during the optimization period will be defined according to two weight groups (5-15kg and >15kg). Current dosing schedule for gabapentin is the following:

  • Day 1 starting dose in mg/kg/day;
  • Day 3 2 times the starting dose in mg/kg/day;
  • Day 5 3 times the starting dose in mg/kg/day;
  • Day 14 2 times the dose of Day 5 in mg/kg/day;
  • Day 21 3 times the dose of Day 5 in mg/kg/day.

Dosing of morphine is largely based on the "WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses", 2012. The guidelines recommended starting dose for immediate release formulation of morphine are '80-200 mcg/kg every 4 hours for infants and 200-500 mcg/kg in 6 divided doses in older children. ' However, due to compliance issues a four times daily regimen (q.i.d) will be used during the titration phase of this protocol for children with body weight >30kg and throughout this study for patients with \<30kg body weight.

The morphine starting dose in this study reflects the lower end of the WHO recommendation with a titration scheduled to reach a maximum daily dose of 1.2 mg/kg/day. Patients \< 30kg BW will have the liquid morphine formulation, 4 times daily throughout the study and patients > 30kg will receive immediate release tablet 4 times daily, during the titration phase and extended release tablets 2 times daily during the maintenance phase.

All subjects that are completing the study or are withdrawn early must be tapered off of the gabapentin. At the visit of Early Termination or End Of Study visit, subjects will be dispensed a taper dose based on their current dose level (the dose of the medicinal product taken during the maintenance period) and should follow the dose tapering as described in the protocol.

Concomitant use of some medications that could interfere with the study will be prohibited. Unrestricted use of paracetamol and/or ibuprofen alone or in combination will be used as rescue therapy any time the patient experiences pain (pain level >4/10 measured with age- appropriate pain scales FLACC, FPS-R or NRS-11) This study includes pharmacokinetic analysis to establish a population pharmacokinetic model adequate to describe the time-course and variability of plasma concentrations of gabapentin and gabapentin plus morphine following repeat dosing in children with chronic pain.

The study includes also an optional exploratory pharmacogenomics study which requires a separate Informed Consent if the parent of the subject agrees to participate. The aims of the exploratory pharmacogenomic research is to better understand inherited genetic factors and their association with clinical assessments, which may include pharmacokinetics of gabapentin, relative susceptibility to drug-drug interactions, predisposition to side effects, and/or patients' response to treatment with gabapentin.

The study foresees also an exploratory metabolomic study that may provide insight in the mechanism of neuropathic pain and the inter-individual variation in drug response.

During this study, it is expected that a maximum of 15.9 mL of blood will be taken from every subject (male and female). Additional 2.0 ml of blood will be required from females of child bearing age for pregnancy testing.

The primary analysis of efficacy will be conducted using ANCOVA with baseline average pain score as a covariate.

The study will be conducted under the supervision of an independent Data Safety Monitoring Committee (DSMC).

03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
3 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 3 months to less than 18 years at screening (V1)
  2. by parent(s) and/or legal guardian according to each country legal requirement.
  3. Assent, where applicable, according to each country legal requirement.Informed (co-) consent of child, where applicable, according to each country legal requirement.
  4. Subjects that meet the diagnostic criteria for neuropathic or mixed pain.
  5. Subjects that present with chronic pain defined as the recurrent or continuous pain persisting more than 3 months.
  6. Subject that present with severe pain as defined by average pain intensity of ≥7 /10 as assessed during a 3-day screening period
  7. Stable underlying disease condition and treatment.
  8. Patients with Chemotherapy Induced Peripheral Neuropathy, when in clinical remission or maintenance phase of their therapeutic protocol.

Exclusion criteria

Exclusion Criteria:

  1. Pain duration of more than 5 years.
  2. Current use of gabapentin.
  3. Current use of strong opioids (morphine, methadone, fentanyl, ketamine, oxycodone).
  4. History of failure to respond to adequate treatment by gabapentin or opioids for neuropathic pain.
  5. History of epileptic condition (except febrile seizure disorder).
  6. Subjects with diagnosis of sickle cell disease.
  7. Subjects that present significant cognitive impairment.
  8. Subjects that present current, controlled or uncontrolled, co-morbid psychiatric diagnosis that can impair pain diagnosis and assessment such as severe depressive conditions or psychosis.
  9. Subjects with history of or current suicidal ideation or behaviour.
  10. Subjects with history of substance abuse in particular opioids.
  11. Subjects under prohibited concomitant medication .
  12. Subjects with a (BMI) for age and gender of \< 5th percentile or > 95th percentile (charts provided as Appendix 3).
  13. Subjects with significant renal impairment, i.e., \< 90 mL/min/1.73 m2 (Revised Schwarz equation).
  14. Subjects with significant hepatic impairment or with (AST) or Alanine Transaminase (ALT) enzymes 3 times the upper limit of the age-specific reference range.
  15. Subjects in need for oral treatment or corticosteroid infiltrations to treat pain caused by infiltration or compression of neural structures, e.g. peripheral nerves or spinal cord.
  16. Subjects with abnormal at the screening visit in the discretion of the Investigator/cardiologist.
  17. Subjects with known allergy, hypersensibility or clinically significant intolerance to gabapentin or any component found in the study drugs.
  18. Subjects with fructose intolerance, diabetes, glucose-galactose malabsorption or lactase-isomaltase deficiency.
  19. Subjects participating in another clinical interventional trial.
  20. Subjects scheduled for surgery or in recovery from surgery occurring within 3 months of baseline assessment.
  21. Female subjects who are pregnant or currently lactating.
  22. Subjects that failed screening or were previously enrolled in this study
  23. Patients with Chemotherapy Induced Peripheral Neuropathy, when in induction phase of their therapeutic protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1

    Gabapentin + Morphine

    Drug: Gabapentin + Morphine

  • Placebo comparator
    Group 2

    Placebo + Morphine

    Drug: Placebo + Morphine

Interventions

  • DrugGabapentin + Morphine

    Drug pages: Gabapentin · Morphine

    Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and \>15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.

  • DrugPlacebo + Morphine

    Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.

06

What researchers measure

Primary outcomes

  1. Pain scores

    Pain scores in the two treatment groups assessed at baseline and at the end of the treatment by age-appropriate pain scales. FLACC (the Faces, Legs, Arms, Cry and Consolability - pts aged 3-24 months) scale composed by 5 categories. Each category is scored on the 0-2 scale, which results in a total score of 0-10, where 0=Relaxed and comfortable, 4-6=Moderate pain, 1-3=Mild discomfort, 7-10=Severe discomfort or pain or both. FPS-R scale (Faces Pain Scale - Revised - pts aged 3-7 years): score is associated with face 0, 2, 4, 6, 8, or 10, where 0 = no pain and 10=very much pain. NRS-11(Numerical Rating Scale - pts aged 8-17 years): numerical rating scale where 0=no pain and 10=worst possible pain

    Time frame: on average of 16 weeks

Secondary outcomes

  1. Percentage of responders to treatments

    Percentage of responders to treatments, defined as subjects with a pain intensity reduction of 30% from baseline. Pain intensity is evaluated using age-appropriate pain scale (FLACC, FPS-R, NRS-11). the FLACC (the Faces, Legs, Arms, Cry and Consolability- pts aged 3-24-months) scale is composed by 5 categories. Each category is scored on the 0-2 scale, which results in a total score of 0-10, where 0=Relaxed and comfortable, 4-6=Moderate pain, 1-3=Mild discomfort, 7-10=Severe discomfort or pain or both. FPS-R (Faces Pain Scale - Revised - pts aged 3-7 years) Score is associated with face 0, 2, 4, 6, 8, or 10, where 0 = no pain and 10=very much pain. NRS-11 (Numerical Rating Scale - pts aged 8-17 years): numerical rating scale where 0=no pain and 10=worst possible pain.

    Time frame: on average of 16 weeks

  2. Daily pain intensity

    Daily pain intensity, assessed by age-appropriate scale (FLACC, FPS-R or NRS-11) during dose optimization. the FLACC (the Faces, Legs, Arms, Cry and Consolability- pts aged 3-24-months) scale is composed by 5 categories. Each category is scored on the 0-2 scale, which results in a total score of 0-10, where 0=Relaxed and comfortable, 4-6=Moderate pain, 1-3=Mild discomfort, 7-10=Severe discomfort or pain or both. FPS-R (Faces Pain Scale - Revised - pts aged 3-7 years) Score is associated with face 0, 2, 4, 6, 8, or 10, where 0 = no pain and 10=very much pain. NRS-11 (Numerical Rating Scale - pts aged 8-17 years): numerical rating scale where 0=no pain and 10=worst possible pain.

    Time frame: an average of 3 weeks

  3. Observational assessment of pain

    Observational assessment of pain using the NRS-11 completed by parents and Investigator (or caregiver) at each visit. NRS-11 (Numerical Rating Scale): numerical rating scale where 0=no pain and 10=worst possible pain.

    Time frame: on average of 16 weeks

  4. Self-assessment of pain for children ≥8 years of age

    Self-assessment of pain for children ≥8 years of age using the FPS-R pain scale at each visit. FPS-R (Faces Pain Scale - Revised) Score is associated with face 0, 2, 4, 6, 8, or 10, where 0 = no pain and 10=very much pain.

    Time frame: on average of 16 weeks

  5. Extent of pain

    Extent of pain evaluated as the number of painful areas using the pain charts at screening visit (V1), randomisation (v2) and EOS visit (V10). The pain charts are body maps (front and back) in which each body section is identified with a number.

    Time frame: on average of 16 weeks

  6. Number of episodes of breakthrough pain

    Number of episodes of breakthrough pain (\>7/10 pain score and use of rescue medications) during treatment period

    Time frame: on average of 15 weeks

  7. Number of rescue interventions required during treatment period

    Number of rescue interventions required during treatment period.

    Time frame: on average of 15 weeks

  8. Number of pain-free days

    Number of pain-free days (\<4/10 average pain score without the use of rescue medications) during treatment period

    Time frame: on average of 15 weeks

  9. Participant dropouts

    Participant dropouts due to lack of adequate pain response.

    Time frame: up to 21 weeks

  10. The total cumulative weight normalized dose of each rescue drug.

    The total cumulative weight normalized dose of each rescue drug.

    Time frame: on average of 16 weeks

  11. Total Summary Score from PedsQL™ scale

    Total score obtained using the PedsQL 4.0 Generic Core Scales (by parent, patient aged 3-17years) and PedsQL Infants Scales (by parent of pts aged 3-24months) at randomisation (V2) and at EOS (V10). The total score is a measure of Health Related Quality of life (HRQoL). Higher scores indicate better HRQOL. PedsQL 4.0 Generic Core Scales is composed by 4 multidimensional scales (Physical Funct, Emotional Funct, Social Funct, School Funct) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). Scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always). PedsQL Infant Scales is composed by 5 multidim. scales (Physical Functioning, Physical Symptoms, Emotional Functioning, Social Functioning, Cognitive Functioning) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). The scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always)

    Time frame: on average of 15 weeks

  12. Physical Health Summary Score from PedsQL™ scale

    Physical Health Score obtained using the PedsQL™ 4.0 Generic Core Scales (by parent, patient aged 3-17 years) and PedsQL™ Infant Scales (by parent, aged 3-24 months) at randomisation (V2) and at EOS (V10). PedsQL™ 4.0 Generic Core Scales is composed by 4 multidimensional scales (Physical Funct, Emotional Funct, Social Funct, School Funct) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). Scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always). PedsQL™ Infant Scales is composed by 5 multidimensional scales (Physical Functioning, Physical Symptoms, Emotional Functioning, Social Functioning, Cognitive Functioning) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). The scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always).

    Time frame: on average of 15 weeks

  13. Psychosocial Health Summary Score from PedsQL™ scale

    Psychosocial Health Score obtained using the PedsQL™ 4.0 Generic Core Scales (by parent, patient aged 3-17 years) and PedsQL™ Infant Scales (by parent, aged 3-24 months) at randomisation (V2) and at EOS (V10). PedsQL™ 4.0 Generic Core Scales is composed by 4 multidimensional scales (Physical Funct, Emotional Funct, Social Funct, School Funct) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). Scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always). PedsQL™ Infant Scales is composed by 5 multidimensional scales (Physical Functioning, Physical Symptoms, Emotional Functioning, Social Functioning, Cognitive Functioning) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). The scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always).

    Time frame: on average of 15 weeks

  14. Acceptability of treatment

    Acceptability of treatment (Five Point Facial Hedonic Scale) at EOS visit (V10). Each face in the scale is related to a score (1=unpleasant; 2=not sure; 3=pleasant).

    Time frame: at week 16

  15. Global satisfaction with treatment

    Global satisfaction with treatment (NRS-11, by parent, patient) at EOS visit (V10). The satisfaction is measeured by the numerical rating scale NRS-11 where 0=not satisfied and 10=fully satisfied

    Time frame: at week 16

  16. Clinical Global Impression of Severity of the subject's condition

    Clinical Global Impression of Severity (CGI-S) for Neuropathic or Mixed Pain Overall Severity Prior to Study Treatment (at randomization - V2) assessed by Investigator. Investigators will rate their impression of the severity of the subject's condition. Scoring: Normal: no signs of pain, Borderline painful, Mildly painful, Moderately painful, Markedly painful, Severely painful, Among the most extremely painful patients.

    Time frame: an average of 15 weeks

  17. Clinical Global Impression of Improvement for pain

    Clinical Global Impression of Improvement (CGI-I) for Neuropathic or Mixed Pain Overall at V6 and EOS visit (V10) assessed by Investigator. Investigators will rate their impression of any change of the subject's overall condition of neuropathic or mixed pain since randomization in the study. Scoring are: Very much improved since the initiation of treatment; Much improved; Minimally improved; No change from baseline (the initiation of treatment); Minimally worse; Much worse; Very much worse since the initiation of treatment.

    Time frame: an average of 15 weeks

  18. Patient/parent Global Impression of Change

    Patient/parent Global Impression of Change (PGIC; by parent, patient) at V6 and EOS visit (V10). Patient/parent will rate their impression of any change of the subject's overall condition of neuropathic or mixed pain since randomization in the study. Scoring are: Very much improved since the initiation of treatment; Much improved; Minimally improved; No change from baseline (the initiation of treatment); Minimally worse; Much worse; Very much worse since the initiation of treatment.

    Time frame: an average of 12 weeks

  19. CL/F

    Primary pharmacokinetic parameters for gabapentin: assessment of apparent clearance (CL/F) and of its variability and precision. In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  20. Vd/F

    Primary pharmacokinetic parameter for gabapentin: assessment of apparent volume of distribution (Vd/F) and of its variability and precision. In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  21. ka

    Primary pharmacokinetic parameter for gabapentin: assessment of absorption rate constant (Ka) and of its precision and variability. In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  22. AUC

    Secondary pharmacokinetic parameter for gabapentin: assessment of Area under the Concentration curve (AUC). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  23. Cmax

    Secondary pharmacokinetic parameter for gabapentin: assessment of peak plasma concentration (Cmax). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  24. Tmax

    Secondary pharmacokinetic parameter for gabapentin: assessment of time at which the Cmax is observed (Tmax). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  25. Css

    Secondary pharmacokinetic parameter for gabapentin: assessment of steady state Concentrations (Css). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  26. Cmin

    Secondary pharmacokinetic parameter for gabapentin: assessment of minimum concentration (Cmin). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  27. Systemic exposure to investigational product

    Systemic exposure to investigational product during maintenance period, as assessed by predicted steady-state concentrations.

    Time frame: an average of 12 weeks

  28. Incidence of Adverse Events

    Incidence of Adverse Events at all visits

    Time frame: up to 21 weeks

  29. Percentage of subjects discontinuing the Trial

    Percentage of subjects discontinuing the Trial due to treatment-emergent adverse events

    Time frame: up to 21 weeks

  30. Aggressive behaviour in children aged >6 years

    Aggressive behaviour in children aged \>6 years using the Retrospective Modified Overt Aggression Scale (R-MOAS) at V2, V6 and EOS visit (V10). The scale includes 4 domains (Verbal Incidents, Incidents Toward Other People, Incidents Involving Property, Incidents Directed Toward Self) each one describing different behaviours. Parents rate the frequency of 16 aggressive behaviors (referred to the past week) in the 4 areas. Numeric weighting amplifies the seriousness of more harmful behaviors in the total score. Higher score indicating more aggressive behavior.

    Time frame: an average of 15 weeks

  31. Suicidal ideation/behaviour in subjects aged 6 years and older

    Suicidal ideation/behaviour in subjects aged 6 years and older using the Columbia - Suicide Severity Rating Scale (C-SSRS) scores before IMP (screening V1), V6, EOS visit (V10) and taper visit (V11). The C-SSRS is divided into 2 sections: Suicidal Ideation and Suicidal Behaviour containing each one 5 "yes" or "no" questions. Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the CSSRS) present at the assessment. A score of 0 is assigned if no ideation is present. Composite endpoints are defined below: Suicidal ideation: A "yes" answer at any time during treatment to any one of the five suicidal ideation questions (Categories 1-5). Suicidal behavior: A "yes" answer at any time during treatment to any one of the five suicidal behavior questions (Categories 6-10). Suicidal ideation or behavior: A "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (Categories 1-10)

    Time frame: an average of 16 weeks

  32. Assessment of blinding

    Assessment of blinding: guess of the subject's treatment group (by Investigator, parents and subject if at adequate maturity level) at V10.

    Time frame: at week 16

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep. 2010 Jul 14;2:52. doi: 10.3410/M2-52. PubMed 21170362 ↗
  • Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain. 2001 Dec;17(4):284-95. doi: 10.1097/00002508-200112000-00002. PubMed 11783808 ↗
  • de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Pasqua OD, Tibboel D, Ceci A, de Wildt SN; GAPP consortium. Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial. Trials. 2019 Jan 15;20(1):49. doi: 10.1186/s13063-018-3169-3. Erratum In: Trials. 2019 Jun 20;20(1):368. doi: 10.1186/s13063-019-3519-9. PubMed 30646965 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Oct 2019, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2017
First posted
Sep 7, 2017
StartActual
Apr 4, 2017
Primary completionActual
Oct 21, 2019
CompletionActual
Oct 21, 2019
Last update
Dec 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03275012
Lead sponsor
Pharmaceutical Research Management srl
Collaborators
European Commission
Responsible party
Sponsor
First posted
Sep 7, 2017
Start date
Apr 4, 2017
Primary completion
Oct 21, 2019
Completion
Oct 21, 2019
Last update
Dec 2, 2019

Study contacts

Saskia De Wildt, MD-PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gabapentin · Morphine

Start the discussion